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Recently, peritumoural (lympho)vascular invasion, assessed on haematoxylin–eosin (HE)-stained slides, was added to the St Gallen
criteria for adjuvant treatment of patients with operable breast cancer (BC). New lymphatic endothelium-specific markers, such as
D2-40, make it possible to distinguish between blood (BVI) and lymph vessel invasion (LVI). The aim of this prospective study was to
quantify and compare BVI and LVI in a consecutive series of patients with BC. Three consecutive sections of all formalin-fixed paraffin-
embedded tissue blocks of 95 BC resection specimens were (immuno)histochemically stained in a fixed order: HE, anti-CD34 (pan-
endothelium) and anti-D2-40 (lymphatic endothelium) antibodies. All vessels with vascular invasion were marked and relocated on
the corresponding slides. Vascular invasion was assigned LVI (CD34" or ~/D2-40") or BVI (CD34"/D2-40~) and intra-
(contact with tumour cells or desmoplastic stroma) or peritumoural. The number of vessels with LVI and BVI as well as the number of
tumour cells per embolus were counted. Results were correlated with clinico-pathological variables. Sixty-six (69.5%) and 36 (37.9%)
patients had, respectively, LVI and BVI. The presence of ‘vascular’ invasion was missed on HE in 20% (peritumourally) and 65%
(intratumourally) of cases. Although LVI and BVI were associated intratumourally (P¼0.02), only peritumoural LVI, and not BVI, was
associated with the presence of lymph node (LN) metastases (pperi¼0.002). In multivariate analysis, peritumoural LVI was the only
independent determinant of LN metastases. Furthermore, the number of vessels with LVI was larger than the number of vessels with
BVI (P¼0.001) and lymphatic emboli were larger than blood vessel emboli (P¼0.004). We demonstrate that it is possible to
distinguish between BVI and LVI in BC specimens using specific lymphatic endothelium markers. This is important to study the
contribution of both processes to BC metastasis. Furthermore, immunohistochemical detection of lymphovascular invasion might be
of value in clinical practice.
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Breast cancer (BC) is the most frequent cause of death in women
between 35 and 55 years of age (Uzzan et al, 2004). Loco-regional
spread and recurrence of the disease can be debilitating, but
metastasis to distant organs is the leading cause of breast cancer
(BC)-related death. One of the very early steps in the metastatic
cascade is (lympho)vascular invasion, or the penetration of
tumour cells into lymph and/or blood vessels in and around the
primary tumour. Therefore, tumour cell emboli in lymph and
blood vessels are considered to be the morphological correlates of
BC metastasising to loco-regional lymph nodes (LNs) and distant
haematogenous sites, respectively. The presence of lymphovascu-
lar invasion indeed has been correlated to the presence of LN
metastases and to poor prognosis in patients with BC (Sampat
et al, 1977; Nealon et al, 1979, 1981; Dawson et al, 1982, 1986;
Weigand et al, 1982; Bettelheim et al, 1984; Berger et al, 1988;
Rosen et al, 1989, 1991; Lee et al, 1990; Clayton, 1991; Clemente
et al, 1992; Neville et al, 1992; Fisher et al, 1993a,b; Lauria et al,
1995). Recently, interest in (lympho)vascular invasion has been
increased owing to addition of peritumoural (lympho)vascular
invasion to the St Gallen criteria for selection of adjuvant systemic
treatment in operable BC (Goldhirsch et al, 2005). In these criteria,
lymphovascular invasion is detected on haematoxylin–eosin (HE)
sections that do not allow distinction between blood vessel
invasion (BVI) and lymph vessel invasion (LVI).
Historically, different methodological problems have hampered
visualisation of LVI and BVI in resection specimens of patients
with BC. One of the major challenges has been to distinguish
intratumoural lymph and blood vessels on HE slides from
retraction artefacts caused by tissue fixation and processing. Most
authors only included vessels with a clear-cut endothelium
(Sampat et al, 1977; Nealon et al, 1979, 1981; Dawson et al, 1982,
1986; Weigand et al, 1982; Bettelheim et al, 1984; Berger et al, 1988;
Rosen et al, 1989, 1991; Orbo et al, 1990; Clayton, 1991; Clemente
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set al, 1992; Neville et al, 1992; Fisher et al, 1993a,b; Pinder et al,
1994; Lauria et al, 1995), missing small and collapsed intra-
tumoural vessels or vessels completely filled with tumour cells.
Therefore, some authors only studied peritumoural LVI and BVI
(Clemente et al, 1992; Neville et al, 1992; Lauria et al, 1995) or used
morphological and topographical criteria to identify LVI (Orbo
et al, 1990).
Another methodological problem has been distinguishing
between blood and lymph vessels. Until recently, the lack of
lymph vessel-specific markers made it very difficult to specifically
study BVI or LVI. Therefore, some authors investigated ‘vascular
invasion’, including both LVI and BVI (Berger et al, 1988; Pinder
et al, 1994). Others tried to distinguish between both using blood
vessel-specific characteristics such as typical blood vessel mor-
phology or the presence of red blood cells or fibrin cloths
(Weigand et al, 1982; Lauria et al, 1995). Lee et al (1986, 1990) used
morphologic and immunohistochemical criteria and more re-
cently, blood vessels were identified based on FVIII-antigen
immunohistochemical or van Gieson elastica stains (Kato et al,
2002, 2003).
During the last decade, several specific markers for lymphatic
endothelium have been discovered, such as Prox-1, a transcription
factor, Lyve-1, a hyaluronan receptor, podoplanin, a glomerular
podocyte membrane protein and D2-40. Recently, it has been
shown that the D2-40 antibody specifically recognises podoplanin
(Schacht et al, 2005) and that D2-40 and podoplanin are the most
sensitive and specific antibodies for the detection of lymphatic
endothelium (Evangelou et al, 2005). In BC, we previously
demonstrated that D2-40 is the best marker for lymphatic
endothelium (Van der Auwera et al, 2005). Used in combination
with panendothelial markers such as CD34 or CD31, it is now
possible to differentiate between BVI and LVI and to study the role
of both processes in BC metastasis. Recent data (reviewed by
Pantel et al) have supported BC metastasis models hypothesising
that lymphatic and haematogenous dissemination in BC are two
complementary and specific pathways (Pantel and Brakenhoff,
2004). Therefore, the aim of this study was to evaluate a technique
using a combined immunohistochemical expression profile to
differentiate on an individual vessel basis between LVI and BVI in
a consecutive series of patients with BC. Furthermore, we obtained
quantitative data on LVI and BVI in BC and correlated the
presence of LVI and BVI to other clinico-pathological variables.
MATERIALS AND METHODS
Patient selection
From 18 March 2005 until 19 August 2005, all tumourectomy,
quadrantectomy or (modified) mastectomy specimens containing
invasive BC examined at the Department of Pathology, General
Hospital AZ St-Augustinus, Wilrijk, Belgium, were prospectively
included in this study after written informed consent. As the
investigators had no access to clinico-pathological data, all 109
included resection specimens were processed and analysed as
described below. When the anonymisation code was broken, one
patient with documented distant metastases and five patients with
a local recurrence were excluded. From eight patients with more
than one resection specimen, only the first was taken into account.
Therefore, 95 patients with operable breast carcinoma were
included in this study. One patient refused to have an axillary
lymphadenectomy, hence no information on LN status was
available in this patient. Table 1 summarises the clinico-
pathological data. Age, tumoural (T) and nodal (N) status,
histological type, tumour grade, oestrogen (ER) and progesterone
receptor (PR) status, p53 and HER2/neu oncoprotein status were
recorded by review of the pathology files. Tumours were
histologically graded according to the Nottingham modification
of the Bloom and Richardson histological grading scheme (Bloom
and Richardson, 1957; Elston, 1987). Tumoural and N status were
assigned according to the tumour node metastasis classification of
the American Joint Committee on Cancer (Green et al, 2002).
Lymph nodes were examined according to the standard pathology
procedure in our institution: HE step sections every 200mm for
sentinel LNs and one HE section every 3mm for non-sentinel LNs.
No immunohistochemical techniques were used for detection of
tumour cells in LNs. Furthermore, the presence and size of a
fibrotic focus and the growth pattern of the tumour were assessed
on the HE slides, as defined previously (Hasebe et al, 1998;
Colpaert et al, 2001, 2003b). A fibrotic focus is defined as a scar-
like area, consisting of fibroblasts and collagen fibres, that
occupies various percentages of the centre of an invasive ductal
carcinoma of the breast. In the infiltrative growth pattern,
carcinoma cells infiltrate between pre-existing breast parenchymal
structures, without significant disturbance of the breast architec-
ture. In the expansive growth pattern, the tumour forms a well-
Table 1 Clinico-pathological data of patients included
N¼95 Clinico-pathological data
Mean age (years) 60.5 (33.5–86.1)
T status
T1 63
T2 27
T3 3
T4 2
N status
N0 52
N1 27
N2 10
N3 5
Histological type
Ductal 72
Lobular 10
Special type 13
Tumour grade
I3 1
II 35
III 29
ER status
Negative 25
Positive 70
PR status
Negative 32
Positive 63
p53 status
Negative 73
Positive 22
HER2/neu status
Negative 91
Positive 4
Fibrotic focus
No 56
o1/3rd tumour diameter 20
41/3rd tumour diameter 19
Growth pattern
Infiltrative 15
Mixed 68
Expansive 12
ER¼oestrogen receptor; N¼nodal; PR¼progesterone receptor; T¼tumoural.
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scircumscribed nodule consisting of carcinoma cells and desmo-
plastic connective tissue. Pre-existing breast parenchymal struc-
tures are not present inside the tumour but are pushed aside by
the expansively growing nodule. The growth pattern is mixed
infiltrative-expansive, when the tumour consists of a central
expansive nodule surrounded by carcinoma cells showing an
infiltrative growth pattern.
(Immuno)histochemistry
After routine histopathological examination, three consecutive
4mm sections of all formalin-fixed paraffin-embedded (FFPE)
tissue blocks containing invasive carcinoma were cut and
numbered. These slides were (immuno)histochemically stained
in a fixed order: the first section of each block was stained with HE,
the second with antibodies against CD34 (panendothelium
marker) and the third with antibodies against D2-40 (lymphatic
endothelium marker). The CD34 and D2-40 immunohisto-
chemistry (IHC) were performed on the Dako Autostainer (Dako,
Glostru ¨p, Denmark) using the Envision Dual Link þ as the
detection system (Dako). The CD34 (dilution 1/50, Clone Qbend10,
Dako) and D2-40 (dilution 1/100, Dako) primary antibodies were
both incubated for 30min.
Assessment of blood and lymph vessel invasion
First, all slides (HE, CD34 and D2-40) were screened for
(lympho)vascular invasion using strict criteria (HE: tumour cells
within an endothelium-lined vessel-like structure; CD34 or D2-40:
tumour cells within an immunohistochemically positive vessel-like
structure). Every slide was assessed by two investigators (GVdE
and CC) without access to the data of other sections of the same
resection specimen or other stainings of the same section. Every
vessel with tumour cell invasion according to the criteria on one of
the three consecutive sections was relocated on the other slides and
assigned BVI or LVI based on the immunohistochemical staining
profile (Figure 1). These blood and lymph vessels were also tracked
on the corresponding HE stain and were scored as ‘picked-up on
HE’ if the vascular invasion had also been marked on HE or
‘missed on HE’ if the vascular invasion had not been seen on HE.
Tumour cell invasion in a vascular structure marked on the HE
stain that was neither D2-40 nor CD34 positive was called
‘overdiagnosis on HE’. Table 2 schematically shows the different
possibilities. Furthermore, the foci of BVI and LVI were scored as
intra- (in contact with tumour cells or desmoplastic stroma) or
peritumoural and the size of every focus of BVI or LVI was
assessed by counting the number of intravascular tumour cells.
Statistical analysis
Statistical analysis was performed with the SPSS 12.0 software
package. A P-valuep0.05 was considered statistically significant, a
0.5oP-valuep0.1 was considered a trend towards statistical
significance. Normality was tested with a Kolmogorov–Smirnov
test assuming normality of data if PX0.2. As continuous data (e.g.
number of vessels with LVI or BVI, size of lymphatic and blood
vessel emboli) were not normally distributed, the median (25–75th
percentile) value is reported and compared between different
groups with a Mann–Whitney U-test. For analysing associations
between categorical variables (e.g. presence of LVI or BVI,
presence of LN metastases, ER status and PR status), the w
2 test
or – when the assumptions of the w
2 test were not met – the
Fisher’s exact test, was used. To build a multivariate model
predicting axillary LN involvement, a logistic regression with
backward procedure including intra- and peritumoural ‘vascular’
invasion, LVI and BVI was performed.
ABC
DEF
Figure 1 Overview of the histological and immunohistochemical stainings on consecutive slides, used to differentiate between BVI (upper row: A, B and
C) and LVI (lower row: D, E and F). Tumour cell emboli are indicated with black arrows. A and D: HE staining showing the presence of vascular invasion. B
and E: On CD34 staining, both blood (C) and lymph (F) vessel endothelium stain positive. Furthermore, normal breast stromal cells are also CD34 positive
(E). E and F: On D2-40 staining, the endothelium of vessels with BVI (B) and LVI (E) are respectively negative and positive. Desmoplastic stromal cells are
also D2-40 positive (C). (BVI¼blood vessel invasion, LVI¼lymph vessel invasion).
Table 2 Decision table for the assessment of LVI or BVI based on the CD34/D2-40 staining profile of the vessel wall
D2-40  D2-40+
CD34  ‘Overdiagnosis’ on HE Lymph vessel ‘Picked up’ or ‘missed’ on HE
CD34 + Blood vessel ‘Picked up’ or ‘missed’ on HE
BVI¼blood vessel invasion; HE¼haematoxylin–eosin; LVI¼lymph vessel invasion.
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sRESULTS
(Lympho)vascular invasion vs number of blocks
A total of 3297 vessels (661 intra and 2636 peritumoural) with LVI
and 135 vessels with BVI (76 intra and 59 peritumoural) were
demonstrated in consecutive sections of 446 FFPE tissue blocks.
The median number of blocks per patient was four (range 1–20).
The number of FFPE blocks investigated was significantly
correlated with the size of the tumour (r¼0.40, Po0.001). Lymph
vessel invasion (P¼0.01) and BVI (Po0.001) were more
frequently demonstrated in larger tumours and the number of
vessels with LVI (r¼0.46, Po0.001) and BVI (r¼0.46, Po0.001)
was correlated with the size of the tumour. The presence of LVI or
BVI was not associated with the number of blocks investigated, but
the number of vessels with LVI (r¼0.34, P¼0.001), not BVI
(r¼0.15, P¼0.15), was correlated with the number of blocks.
Blood vessel vs lymph vessel invasion
Lymph vessel invasion was more frequent than BVI. Sixty-six
(69.5%) patients had LVI (eight only intratumoural, 35 only
peritumoural and 23 both intra- and peritumoural) and 36 (37.9%)
patients had BVI (12 only intratumoural, eight only peritumoural
and 16 both intra- and peritumoural). In 28 (29.5%) resection
specimens, both LVI and BVI were found and in eight and 38
resection specimens, only BVI or LVI were found, respectively. The
presence of LVI was associated with the presence of BVI
intratumourally (P¼0.02), but not peritumourally (P¼0.11).
Furthermore, LVI was more extensive than BVI and lymphatic
emboli were larger than blood vessel emboli. In seven cases, more
than 100 vessels with LVI were found, whereas the maximum
number of vessels with BVI was 16. In cases with either LVI or BVI,
the median numbers of lymph and blood vessels with vascular
invasion were, respectively, six (2–20.5) and three (1–5.75)
(P¼0.004) and the median sizes of the lymphatic and blood
vessel emboli were 16 (8–35) and eight (5–11) intravascular
tumour cells (P¼0.001). If both LVI and BVI were present, the
median of the fraction of lymph vessels of the total number of
vessels with vascular invasion was 80.0% (50.0–95.4%). Figure 2
represents differences in extent and size between LVI and BVI. The
median number of vessels with LVI in cases with both LVI and BVI
was significantly higher than the median number of vessels with
BVI in cases with both LVI and BVI (P¼0.003) or in cases with
BVI only (P¼0.04). Furthermore, the median number of tumour
cells/embolus was significantly higher in lymph vessel emboli than
in blood vessel emboli, both in cases with LVI/BVI only (P¼0.03)
or in cases with both LVI or BVI (P¼0.02).
Immmunohistochemistry vs HE
On HE-stained sections it is impossible to differentiate between
blood and lymph vessels. Therefore, the presence of ‘vascular’
invasion, including both BVI and LVI, was assessed. When only
the results of this assessment were taken into account, 54 (56.8%)
patients had vascular invasion (five only intratumoural, 38 only
peritumoural and 11 both intra- and peritumoural). Both intra-
and peritumourally, vascular invasion assessed on HE was
associated with LVI (pintra¼0.03, pperio0.001) and with BVI
(pintra¼0.01, pperi¼0.008). Nevertheless, the presence of LVI and
BVI was missed intratumourally in 71.0 and 67.9% of immuno-
histochemically positive cases, respectively. Peritumourally, only
22.4 and 25% of cases with, respectively, LVI and BVI were missed
on HE. Furthermore, not only the presence of LVI and BVI was
underestimated on HE, but also the extent. On HE, vessels with
BVI were more frequently missed than vessels with LVI: the
median percentage of vessels with BVI and LVI seen on HE was,
respectively, 0.0 (0.0–31.3) and 26.8 (0.0–54.0) (P¼0.009).
Overdiagnosis of ‘vascular’ invasion on one or more HE-stained
slides was seen in 23 (24.2%) patients.
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Figure 2 Differences in extent (left, black) and in size of tumour cell emboli (right, grey) between LVI (circles) and BVI (squares) in cases with LVI only (full
circles), BVI only (open squares) or both LVI and BVI (open circles and full squares). The median value for each group is marked with a horizontal line and
statistically significant differences are indicated on top (LVI¼lymph vessel invasion, BVI¼blood vessel invasion).
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pathological variables
The presence of peritumoural (P¼0.01) ‘vascular’ invasion on HE
was associated with the presence of LN metastases. The presence of
peritumoural LVI was strongly associated with the presence of LN
metastases (P¼0.002). For intratumoural LVI, a trend to a positive
association was found (P¼0.07). Neither the presence of intra-,
nor the presence of peritumoural BVI was associated with LN
involvement (Table 3). The negative predictive value for intra-
tumoural ‘vascular’ invasion, peritumoural ‘vascular’invasion,
intratumoural LVI, peritumoural LVI, intratumoural BVI and
peritumoural BVI were 60.3, 68.0, 61.9, 75.0, 57.6 and 60%,
respectively. The positive predictive values were, respectively, 68.8,
57.1, 58.1, 56.5, 58.1, 50.0 and 58.3%. Multivariate logistic
regression analysis revealed that peritumoural LVI (b¼1.38,
P¼0.003) was the most important determinant of axillary
involvement. Table 4 represents the associations between the
presence of LVI and BVI and other clinico-pathological variables.
DISCUSSION
We used the combination of the lymph endothelium-specific
marker D2-40 and the panendothelial marker CD34 to detect and
distinguish between LVI and BVI. LVI and BVI were found in 69.5
and 37.9% of patients, respectively. Other authors report LVI and
especially BVI in BC to be less frequent: prevalences of LVI and
BVI range from 8.8 (Nime et al, 1977) to 86% (Kahn and Marks,
2002) and from 4.2 (Lauria et al, 1995) to 33% (Kato et al, 2002),
respectively. The presence and extent of LVI and BVI correlated
with the size of the tumour and only the extent of LVI correlated
with the number of blocks investigated. Therefore, the high
number of FFPE tissue blocks that was investigated per resection
specimen cannot fully explain the increased frequency of LVI and
BVI in this study. On the contrary, the use of IHC with endothelial
markers to detect LVI and BVI accounts for their high prevalence.
Immunohistochemistry is a very sensitive and specific technique.
In our study, the presence of LVI or BVI was missed on HE in 71.0
and 67.9% of specimens intratumourally and in 20–25% of
specimens peritumourally. Furthermore, also the extent of LVI and
BVI was underestimated on HE. Differences in endothelial markers
and in study populations further lead to differences in LVI and BVI
prevalence. For LVI, the highest prevalences are found in the
studies with D2-40 and podoplanin. Kahn et al demonstrated
lymphatic invasion in 44% of LN negative and 86% of LN positive
(overall 66%) BC patients (Kahn and Marks, 2002). Recently, it has
been shown that the D2-40 antibody specifically recognises
podoplanin (Schacht et al, 2005) and that both antibodies against
podoplanin and D2-40 can be regarded as reference standards
for the identification of lymphatic vessels in most settings. Both
Table 3 Cross-tabs showing the association between LVI (upper part)
or BVI (lower part) and LN involvement
LN involvement
No Yes
‘vascular’invasion (assessed on HE)
Intratumoural (P¼0.03)
No 47 31
Yes 5 11
Peritumoural (P¼0.01)
No 31 14
Yes 21 28
LVI (assessed on IHC)
Intratumoural (P¼0.07)
No 39 24
Yes 13 18
Peritumoural (P¼0.002)
No 27 9
Yes 25 33
BVI (assessed on IHC)
Intratumoural (P¼0.50)
No 38 28
Yes 14 14
Peritumoural (P¼0.12)
No 42 28
Yes 10 14
BVI¼blood vessel invasion; HE¼haematoxylin–eosin; IHC¼immunolistochemis-
try; LN¼lymph node; LVI¼lymph vessel invasion.
Table 4 Correlation between clinico-pathological variables and LVI and
BVI
LVI BVI
Pos Neg Pos Neg
T status
T1 39 24 P*¼0.03 17 46 P*¼0.001
T2 23 4 17 10
T 3 21 12
T 4 20 11
N status
N0 33 19 P¼0.05 16 36 P¼0.14
N1 18 9 11 16
N2 10 0 5 5
N 3 50 41
Histological type
IDA 55 17 P¼0.009 32 40 P¼0.07
I L A 37 28
Special Type 8 5 2 11
Tumour grade
11 5 1 6 P¼0.005 4 27 Po0.001
2 26 9 12 23
3 25 4 20 9
ER
Pos 47 23 P¼0.41 25 45 P¼0.46
Neg 19 6 11 14
PR
Pos 42 21 P¼0.41 21 42 P¼0.20
Neg 24 8 15 17
p53
Pos 18 4 P¼0.15 10 12 P¼0.40
Neg 48 25 26 47
HER2/neu
Pos 3 1 P¼1.00 3 1 P¼0.15
Neg 63 28 33 58
Fibrotic focus
Absent 33 23 P¼0.02 15 41 P¼0.005
o1/3th tumour diameter 18 2 8 12
41/3th tumour diameter 15 4 13 6
Growth pattern
Infiltrative 9 6 P¼0.66 2 13 P¼0.09
Mixed 48 20 28 40
Expansive 9 3 6 6
BVI¼blood vessel invasion; ER¼oestrogen receptor; LVI¼lymph vessel invasion;
N¼nodal; Neg¼negative; Pos¼positive; PR¼progesterone receptor;
T¼tumoural. P*: P-value of a 2 2 table only including T1 and T2 tumours.
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specificity for lymphatic endothelium of over 95% (Evangelou
et al, 2005). We previously showed that in BC, D2-40 is the best
marker for lymphatic endothelium (Van der Auwera et al, 2005).
Most studies investigating BVI in BC used FVIII or a combination
of FVIII and van Gieson elastica staining. Nevertheless, CD34 or
CD31 is prefered to visualise blood vessels in solid tumours
(Vermeulen et al, 1996, 2002), as FVIII expression is absent in
some tumour capillaries that can lead to underestimation of the
presence and extent of BVI (Vermeulen et al, 1995). As CD34 is not
very specific for blood vessels, especially in tumour tissue, the
combination with a specific lymphatic endothelium marker such
as D2-40 is necessary to differentiate between LVI and BVI. In the
present study, more than 50% of lymph vessels did show CD34
expression (data not shown). CD31 might be a more specific
endothelial marker than CD34, nevertheless the latter was prefered
in this study, as CD31 positivity of inflammatory cells might
hamper interpretation.
Recently, peritumoural lymphovascular invasion has been
included in the St Gallen guidelines for adjuvant therapy of
operable breast carcinoma patients (Goldhirsch et al, 2005). In
these criteria, peritumoural lymphovascular invasion is assessed
on HE-stained sections during routine pathological examination,
making it impossible to differentiate between LVI and BVI. In our
data set, peritumoural ‘vascular’ invasion on HE and peritumoural
LVI, not BVI were correlated with the presence of LN metastasis,
still the only most important prognostic factor in BC. Multivariate
analysis showed peritumoural LVI to be the most important
determinant for the presence of LN metastases. Together with the
increase in negative predictive value to 75% for peritumoural LVI,
our results suggest that immunohistochemical detection of
lymphovascular invasion and differentiation between LVI and
BVI might be of value in clinical practice. Further studies are
needed to address this issue.
If LVI and BVI are the morphological correlates of BC cells
metastasising, respectively, via the lymphatic and the haemato-
genous route, our data support BC metastasis models stating that
haematogenous and lymphatic metastasis are two complementary
but specific metastasis pathways in BC. These newer models are in
contrast with older models explaining BC metastasis as a stepwise
cascade going from primary tumour via regional LNs to distant
sites (Pantel and Brakenhoff, 2004). Only peritumoural LVI, and
not BVI, was associated with the presence of LN metastases. Other
authors found a correlation between BVI and LN metastases
(Lauria et al, 1995; Kato et al, 2003). This might be due to the fact
that the methods they used were too insensitive to discriminate
between LVI and BVI, leading to misinterpretation of BVI as LVI.
Another factor contributing to the correlation between BVI and LN
status in some studies might be the association between LVI and
BVI. In our study, the presence of LVI was associated with the
presence of BVI intratumourally, not peritumourally. As BVI is
correlated with angiogenesis (Kato et al, 1999, 2001, 2003) and LVI
is correlated with lymphangiogenesis (Schoppmann et al, 2004),
the association between LVI and BVI might be due to the cross-
interaction between lymphangiogenesis and hemangiogenesis. The
hemangiogenic factors vascular endothelial growth factor (VEGF)-
A, basic fibroblast growth factor, angiopoietin-1 and -2 and
platelet-derived growth factor have been shown to induce
lymphangiogenesis and the lymphangiogenic factor VEGF-C can
also induce hemangiogenesis (reviewed in Cao, 2005; Tammela
et al, 2005). In a study of 29 invasive breast carcinomas, Choi et al
(2005) reported a correlation between blood and lymph vessel
microvessel density. The presence of a fibrotic focus is a surrogate
marker for hypoxia-driven angiogenesis (Colpaert et al, 2003a) and
for lymphangiogenesis in BC (Van der Auwera et al, 2005). In the
present study, the presence of a fibrotic focus was indeed
correlated with the presence of both LVI and BVI. The hypothesis
that blood and lymph vessels are not just different routes that
cancer cells can use to metastasise, but are characterised by a
different biology is furthermore sustained by the fact that some
patients exclusively show BVI or LVI and by the differences in size
and number between LVI and BVI. In BVI, less vessels are involved
and the size of the tumour emboli is smaller than in LVI. Very
extensive vascular invasion is not found in BVI. To what extent
these differences influence the metastatic capacity of both path-
ways remains to be elucidated.
In conclusion, we demonstrated that the described immunohis-
tochemical technique made it possible to discriminate between
BVI and LVI in BC and enabled a more sensitive detection of LVI
and BVI and a better assessment of the extent of both than on
conventional HE stains. Furthermore, our data demonstrate that
most (lympho)vascular invasion in BC is LVI and that lymph
vessel tumour emboli are larger than blood vessel tumour emboli.
This suggests that LVI and BVI are not just different routes of BC
metastasis, but that both pathways are characterised by a different
biology.
ACKNOWLEDGEMENTS
G Van den Eynden is a research assistant of the Fund for Scientific
Research Flanders. S Van Laere is a predoctoral assistant of the
University of Antwerp. This work was supported by the Fund for
Scientific Research Flanders Grant L.3.058.06N. We thank J Weyler
for directing the statistical analysis and the technical staff of the
Laboratory for Pathology of the GH St-Augustinus for expert
technical assistance.
REFERENCES
Berger U, Bettelheim R, Mansi J, Easton D, Coombes R, Neville A (1988)
The relationship between micrometastases in the bone marrow,
histopathologic features of the primary tumor in breast cancer and
prognosis. Am J Clin Pathol 90: 1
Bettelheim R, Penman H, Thornton-Jones H, Neville A (1984) Prognostic
significance of peritumoral vascular invasion in breast cancer. Br J
Cancer 50: 771
Bloom H, Richardson W (1957) Histological grading and prognosis in
breast cancer: a study of 1409 cases of which 359 have been followed for
15 years. Br J Cancer 11: 359
Cao Y (2005) Opinion: emerging mechanisms of tumour lymphangiogen-
esis and lymphatic metastasis. Nat Rev Cancer 5: 735
Choi W, Lewis M, Lawson D, Q Y-G, Birdsong G, Cotsonis G, Cohen C,
Young A (2005) Angiogenic and lymphangiogenic microvessel density in
breast carcinoma: correlation with clinicopathologic parameters and
VEGF-family gene expression. Mod Pathol 18: 143
Clayton F (1991) Pathologic correlates of survival in 378 lymph node-
negative infiltrating ductal breast carcinomas. Mitotic count is the best
single predictor. Cancer 68: 1309
Clemente C, Boracchi P, Andreola S, Del Vecchio M, Veronesi P, Rilke F
(1992) Peritumoral lymphatic invasion in patients with node-negative
mammary duct carcinoma. Cancer 69: 1396
Colpaert C, Vermeulen P, Van Beest P, Goovaerts G, Weyler J, Van Dam P,
Dirix L, Van Marck E (2001) Intratumoral hypoxia resulting in the
presence of a fibrotic focus is an independent predictor of early distant
relapse in lymph node-negative breast cancer patients. Histopathology
39: 416
Colpaert C, Vermeulen P, Van Beest P, Soubry A, Goovaerts G,
Dirix L, Harris A, Van Marck EA (2003b) Cutaneous breast
cancer deposits show distinct growth patterns with different
degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology
42: 530
Blood and lymph vessel invasion in breast cancer
GG Van den Eynden et al
1648
British Journal of Cancer (2006) 94(11), 1643–1649 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sColpaert C, Vermeulen P, Fox S, Harris A, Dirix LY, Van Marck EA (2003a)
The presence of a fibrotic focus in invasive breast carcinoma correlates
with the expression of carbonic anhydrase IX and is a marker of hypoxia
and poor prognosis. Breast Cancer Res Treat 81: 137
Dawson P, Ferguson D, Karrison T (1982) The pathological findings of
breast cancer in patients surviving 25 years after radical mastectomy.
Cancer 50: 2131
Dawson P, Karrison T, Ferguson D (1986) Histologic features associated
with long-term survival in breast cancer. Hum Pathol 17: 1015
Elston CW (1987) Grading of invasive carcinoma of the breast. In
Diagnostic Histopathology of the Breast, Page DL, Anderson TJ (eds), p
302. New York: Churchill Livingstone
Evangelou E, Kyzas PA, Trikalinos T (2005) Comparison of the diagnostic
accuracy of lymphatic endothelium markers: Bayesian approach. Mod
Pathol 18: 1490
Fisher E, Anderson S, Redmond C, Fisher B (1993a) Pathologic findings
from the National Surgical Adjuvant Breast Project protocol B-06. 10-
year pathologic and clinical prognostic discriminants. Cancer 71: 2507
Fisher E, Costantino J, Fisher B, Redmond C (1993b) Pathologic findings
from the National Surgical Adjuvant Breast Project (Protocol 4).
Discriminants for 15-year survival. National Surgical Adjuvant Breast
and Bowel Project Investigators. Cancer 71: 2141
Goldhirsch A, Glick J, Gelber R, Coates A, Thurlimann B, Senn H (2005)
Meeting highlights: international expert consensus on the primary
therapy of early breast cancer 2005. Ann Oncol 16: 1569
Green F, Balch C, Fleming I, Fritz A, Haller D, Morrow M, Page D (2002)
AJCC Cancer Staging Handbook: 6/e TNM Classification of Malignant
Tumors, p 140. New York: Springer-Verlag
Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y, Yamamoto H,
Mukai K (1998) Fibrotic focus in infiltrating ductal carcinoma of the
breast: a significant histopathological prognostic parameter for predict-
ing the long-term survival of the patients. Breast Cancer Res Treat 49: 195
Kahn H, Marks A (2002) A new monoclonal antibody, D2-40, for detection
of lymphatic invasion in primary tumors. Lab Invest 82: 1255
Kato T, Kameoka S, Kimura T, Nishikawa T, Kasajima T (2001)
Angiogenesis and blood vessel invasion as prognostic indicators for
node-negative breast cancer. Breast Cancer Res Treat 65: 203
Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M (2002) Blood
vessel invasion as a predictor of long-term survival for Japanese patients
with breast cancer. Breast Cancer Res Treat 73: 1
Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M (2003) The
combination of angiogenesis and blood vessel invasion as a prognostic
indicator in primary breast cancer. Br J Cancer 88: 1900
Kato T, Kimura T, Ishii N, Fujii A, Yamamoto K, Kameoka S, Nishikawa T,
Kasajima T (1999) The methodology of quantitation of microvessel
density and prognostic value of neovascularization associated with long-
term survival in Japanese patients with breast cancer. Breast Cancer Res
Treat 53: 19
Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C,
Varriale E, Pettinato G, Panico L, Petrella G, Et A (1995) The prognostic
value of lymphatic and blood vessel invasion in operable breast cancer.
Cancer 76: 1772
Lee A, Delellis R, Silverman M, Heatley GJ, Wolfe H (1990) Prognostic
significance of peritumoral lymphatic and blood vessel invasion in node-
negative carcinoma of the breast. J Clin Oncol 8: 1457
Lee A, Delellis R, Silverman M, Wolfe H (1986) Lymphatic and blood vessel
invasion in breast carcinoma: a useful prognostic indicator? Hum Pathol
17: 984
Nealon TJ, Nkongho A, Grossi C, Gillooley J (1979) Pathologic identifica-
tion of poor prognosis stage I (T1N0M0) cancer of the breast. Ann Surg
190: 129
Nealon TJ, Nkongho A, Grossi C, Ward R, Nealon C, Gillooley J (1981)
Treatment of early cancer of the breast (T1N0M0 and T2N0M0) on the
basis of histologic characteristics. Surgery 89: 279
Neville A, Bettelheim R, Gelber RD, Save-Soderbergh J, Davis BW, Reed R,
Torhorst J, Golouh R, Peterson H, Price K, Et A (1992) Factors predicting
treatment responsiveness and prognosis in node-negative breast cancer.
The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:
696
Nime F, Rosen P, Thaler HT, Ashikari R, Urban J (1977) Prognostic
significance of tumor emboli in intramammary lymphatics in patients
with mammary carcinoma. Am J Surg Pathol 1: 25
Orbo A, Stalsberg H, Kunde D (1990) Topographic criteria in the diagnosis
of tumor emboli in intramammary lymphatics. Cancer 66: 972
Pantel K, Brakenhoff R (2004) Dissecting the metastatic cascade. Nat Rev
Cancer 4: 448
Pinder S, Ellis I, Galea M, O’rouke S, Blamey RW, Elston C (1994)
Pathological prognostic factors in breast cancer. III. Vascular invasion:
relationship with recurrence and survival in a large study with long-term
follow-up. Histopathology 24: 41
Rosen P, Groshen S, Kinne DW (1991) Prognosis in T2N0M0 stage I breast
carcinoma: a 20-year follow-up study. J Clin Oncol 9: 1650
Rosen PP, Groshen S, Saigo P, Kinne DW, Hellman S (1989) Pathological
prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast
carcinoma: a study of 644 patients with median follow-up of 18 years.
J Clin Oncol 7: 1239
Sampat M, Sirsat M, Gangadharan P (1977) Prognostic significance of
blood vessel invasion in carcinoma of the breast in women. J Surg Oncol
9: 623
Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong Y, Detmar M (2005)
Up-regulation of the lymphatic marker podoplanin, a mucin-type
transmembrane glycoprotein, in human squamous cell carcinomas and
germ cell tumors. Am J Pathol 166: 913
Schoppmann S, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista
E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R (2004)
Prognostic value of lymphangiogenesis and lymphovascular invasion in
invasive breast cancer. Ann Surg 240: 306
Tammela T, Petrova TV, Alitalo K (2005) Molecular lymphangiogenesis:
new players. Trends Cell Biol 15: 434
Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a
prognostic factor in women with breast cancer: a systematic review of the
literature and meta-analysis. Cancer Res 64: 2941
Van Der Auwera I, Van Den Eynden GG, Colpaert C, Van Laere SJ, Van
Dam P, Van Marck EA, Dirix L, Vermeulen P (2005) Tumor
lymphangiogenesis in inflammatory breast carcinoma: a histomorpho-
metric study. Clin Cancer Res 11: 7637
Vermeulen P, Gasparini G, Fox S, Colpaert C, Marson L, Gion M, Belien J,
De Waal RM, Van Marck E, Magnani E, Weidner N, Harris A, Dirix LY
(2002) Second international consensus on the methodology and criteria
of evaluation of angiogenesis quantification in solid human tumours. Eur
J Cancer 38: 1564
Vermeulen P, Gasparini G, Fox S, Toi M, Martin L, Mcculloch P, Pezzella F,
Viale G, Weidner N, Harris A, Dirix LY (1996) Quantification of
angiogenesis in solid human tumours: an international consensus on the
methodology and criteria of evaluation. Eur J Cancer 32A: 2474
Vermeulen P, Verhoeven D, Fierens H, Hubens G, Goovaerts G, Van Marck
E, De Bruijn EA, Van Oosterom AT, Dirix LY (1995) Microvessel
quantification in primary colorectal carcinoma: an immunohisto-
chemical study. Br J Cancer 71: 340
Weigand R, Isenberg W, Russo J, Brennan MJ, Rich M (1982) Blood vessel
invasion and axillary lymph node involvement as prognostic indicators
for human breast cancer. Cancer 50: 962
Blood and lymph vessel invasion in breast cancer
GG Van den Eynden et al
1649
British Journal of Cancer (2006) 94(11), 1643–1649 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s